Raia Drogasil (OTCMKTS:RADLY - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05, Zacks reports. Raia Drogasil had a net margin of 2.99% and a return on equity of 20.12%.
Raia Drogasil Stock Down 5.4%
Shares of OTCMKTS:RADLY traded down $0.15 on Tuesday, hitting $2.70. 25,105 shares of the company's stock were exchanged, compared to its average volume of 83,417. The firm's 50-day moving average is $3.72 and its 200 day moving average is $4.07. The company has a market capitalization of $3.55 billion and a PE ratio of 17.98. Raia Drogasil has a 1-year low of $2.63 and a 1-year high of $5.34. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.58 and a current ratio of 1.41.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group upgraded shares of Raia Drogasil to a "buy" rating and set a $5.20 price objective on the stock in a report on Sunday, October 18th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $5.20.
Read Our Latest Stock Report on Raia Drogasil
Raia Drogasil Company Profile
(
Get Free Report)
Raia Drogasil, now operating under the name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a network of pharmacies offering prescription medicines, over-the-counter drugs, vitamins, personal care products, beauty items and other health-related merchandise.
The company also provides digital purchasing and delivery services through its online channels, supporting customers with prescription fulfillment, health products and related services. Its operations include pharmacy-based healthcare initiatives designed to complement its retail business and improve access to everyday healthcare.
RD Saúde was created in 2011 through the merger of Drogasil and Droga Raia, two established Brazilian pharmacy chains.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Raia Drogasil, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Raia Drogasil wasn't on the list.
While Raia Drogasil currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
